The EZH2 inhibitor EPZ6438 significantly potentiated the activity of CYH33 against ESCC cells as well as PDXs accompanied by enhanced inhibition of cell cycle progression. This evidence concerns the gene EZH2 and esophageal squamous cell carcinoma.